calciumfolinat ebewe 10 mg/ml concetrate for solution for infusion
ebewe pharma ges.m.b.h. nfg.kg - Калциев Фолинат - 10 mg/ml concetrate for solution for infusion
calcium folinate actavis 10 mg/ml solution for injection/infusion
actavis group ptc ehf. - 10 mg/ml solution for injection/infusion
calcium folinate stada, sol.inj.12.7mg/ml -10ml; 20ml; 50ml; 100ml
stada arzneimittel ag - Калциев Фолинат -
calcium folinate sandoz 10 mg/ml solution for injection/infusion
10 mg/ml solution for injection/infusion
calcium folinate alupharma 10 mg/ml solution for injection/infusion
10 mg/ml solution for injection/infusion
bendafolin 10 mg/ml solution for injection
lyomark pharma gmbh - Калциев Фолинат - 10 mg/ml solution for injection
shingrix
glaxosmithkline biologicals sa - recombinant varicella zoster virus glycoprotein e - Херпес Зостер - Ваксини - shingrix is indicated for prevention of herpes zoster (hz) and post-herpetic neuralgia (phn), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of hz. Използването на shingrix трябва да бъде в съответствие с официалните препоръки.
nuvaxovid
novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. Използването на тази ваксина трябва да бъде приложена в съответствие с официалните препоръки. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. Използването на тази ваксина трябва да бъде приложена в съответствие с официалните препоръки.
arexvy
glaxosmithkline biologicals s.a. - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - Инфекции на респираторния синцитиален вирус - Ваксини - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. Използването на тази ваксина трябва да бъде приложена в съответствие с официалните препоръки.